Skip to main content
Top
Published in: Clinical Reviews in Allergy & Immunology 3/2014

01-06-2014

Novel Approaches to Food Allergy

Authors: Yao-Hsu Yang, Bor-Luen Chiang

Published in: Clinical Reviews in Allergy & Immunology | Issue 3/2014

Login to get access

Abstract

Food allergies have increased in recent decades. However, they cannot be effectively treated by the current management, which is limited to the identification and avoidance of foods that induce allergies and to the use of medicines for symptoms relief. To meet the medical need of prevention and cure of food allergies, several therapeutic strategies are under investigation. Some newly developed biologics such as anti-IgE antibody and anti-interleukin (IL)-5 antibody directed against significant molecules in the allergic process have shown their potential for the treatment of food allergies. Allergen-specific immunotherapy is the therapy that induces immune tolerance and may reduce the need for conventional medication, severity of allergic symptoms and eliminate hypersensitivity. In this article, clinical studies of immunotherapy via subcutaneous, oral, sublingual, and epicutaneous routes are extensively reviewed for their safety and effectiveness on various food allergies. In addition, to reduce the risk of anaphylaxis and increase toleragenic immunity, many studies are focusing on the modification of traditional allergens used for immunotherapy. Moreover, a Chinese herbal formulation with potential anti-allergic effects is being evaluated for its efficacy in patients with peanut allergy. Although more studies are needed, accumulated data of current studies represent compelling evidence of curative effects of some strategies and give a hope that food allergies are likely to be successfully treated in the future.
Literature
2.
go back to reference Sicherer SH, Munoz-Furlong A, Godbold JH, Sampson HA (2010) US prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year follow-up. J Allergy Clin Immunol 125:1322–1326PubMedCrossRef Sicherer SH, Munoz-Furlong A, Godbold JH, Sampson HA (2010) US prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year follow-up. J Allergy Clin Immunol 125:1322–1326PubMedCrossRef
6.
go back to reference Grimbaldeston MA, Metz M, Yu M, Tsai M, Galli SJ (2006) Effector and potential immunoregulatory roles of mast cells in IgE-associated acquired immune responses. Curr Opin Immunol 18:751–760PubMedCrossRef Grimbaldeston MA, Metz M, Yu M, Tsai M, Galli SJ (2006) Effector and potential immunoregulatory roles of mast cells in IgE-associated acquired immune responses. Curr Opin Immunol 18:751–760PubMedCrossRef
8.
go back to reference Decker WW, Campbell RL, Manivannan V, Luke A, St Sauver JL et al (2008) The etiology and incidence of anaphylaxis in Rochester, Minnesota: a report from the Rochester Epidemiology Project. J Allergy Clin Immunol 122:1161–1165PubMedCentralPubMedCrossRef Decker WW, Campbell RL, Manivannan V, Luke A, St Sauver JL et al (2008) The etiology and incidence of anaphylaxis in Rochester, Minnesota: a report from the Rochester Epidemiology Project. J Allergy Clin Immunol 122:1161–1165PubMedCentralPubMedCrossRef
9.
go back to reference Scheinfeld N (2005) Omalizumab: a recombinant humanized monoclonal IgE-blocking antibody. Dermatol Online J 11:2PubMed Scheinfeld N (2005) Omalizumab: a recombinant humanized monoclonal IgE-blocking antibody. Dermatol Online J 11:2PubMed
10.
go back to reference Leung DY, Sampson HA, Yunginger JW, Burks AW Jr, Schneider LC et al (2003) Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 348:986–993PubMedCrossRef Leung DY, Sampson HA, Yunginger JW, Burks AW Jr, Schneider LC et al (2003) Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 348:986–993PubMedCrossRef
11.
go back to reference Sampson HA, Leung DY, Burks AW, Lack G, Bahna SL et al (2011) A phase II, randomized, double-blind, parallel group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol 127:1309–1310PubMedCrossRef Sampson HA, Leung DY, Burks AW, Lack G, Bahna SL et al (2011) A phase II, randomized, double-blind, parallel group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol 127:1309–1310PubMedCrossRef
12.
go back to reference Rafi A, Do LT, Katz R, Sheinkopf LE, Simons CW et al (2010) Effects of omalizumab in patients with food allergy. Allergy Asthma Proc 31:76–83PubMedCrossRef Rafi A, Do LT, Katz R, Sheinkopf LE, Simons CW et al (2010) Effects of omalizumab in patients with food allergy. Allergy Asthma Proc 31:76–83PubMedCrossRef
13.
go back to reference Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH et al (2006) Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 117:134–140PubMedCrossRef Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH et al (2006) Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 117:134–140PubMedCrossRef
14.
go back to reference Kamin W, Kopp MV, Erdnuess F, Schauer U, Zielen S et al (2010) Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously. Pediatr Allergy Immunol 21:e160–e165PubMedCrossRef Kamin W, Kopp MV, Erdnuess F, Schauer U, Zielen S et al (2010) Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously. Pediatr Allergy Immunol 21:e160–e165PubMedCrossRef
16.
go back to reference Garrett JK, Jameson SC, Thomson B, Collins MH, Wagoner LE et al (2004) Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol 113:115–119PubMedCrossRef Garrett JK, Jameson SC, Thomson B, Collins MH, Wagoner LE et al (2004) Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol 113:115–119PubMedCrossRef
17.
go back to reference Straumann A, Conus S, Grzonka P, Kita H, Kephart G et al (2010) Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut 59:21–30PubMedCrossRef Straumann A, Conus S, Grzonka P, Kita H, Kephart G et al (2010) Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut 59:21–30PubMedCrossRef
20.
go back to reference Akdis CA, Akdis M (2011) Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 127:18–27PubMedCrossRef Akdis CA, Akdis M (2011) Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 127:18–27PubMedCrossRef
21.
go back to reference Oppenheimer JJ, Nelson HS, Bock SA, Christensen F, Leung DY (1992) Treatment of peanut allergy with rush immunotherapy. J Allergy Clin Immunol 90:256–262PubMedCrossRef Oppenheimer JJ, Nelson HS, Bock SA, Christensen F, Leung DY (1992) Treatment of peanut allergy with rush immunotherapy. J Allergy Clin Immunol 90:256–262PubMedCrossRef
22.
go back to reference Nelson HS, Lahr J, Rule R, Bock A, Leung D (1997) Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. J Allergy Clin Immunol 99:744–751PubMedCrossRef Nelson HS, Lahr J, Rule R, Bock A, Leung D (1997) Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. J Allergy Clin Immunol 99:744–751PubMedCrossRef
23.
go back to reference Katelaris CH (2010) Food allergy and oral allergy or pollen-food syndrome. Curr Opin Allergy Clin Immunol 10:246–251PubMedCrossRef Katelaris CH (2010) Food allergy and oral allergy or pollen-food syndrome. Curr Opin Allergy Clin Immunol 10:246–251PubMedCrossRef
24.
go back to reference Asero R (1998) Effects of birch pollen-specific immunotherapy on apple allergy in birch pollen-hypersensitive patients. Clin Exp Allergy 28:1368–1373PubMedCrossRef Asero R (1998) Effects of birch pollen-specific immunotherapy on apple allergy in birch pollen-hypersensitive patients. Clin Exp Allergy 28:1368–1373PubMedCrossRef
25.
go back to reference Bucher X, Pichler WJ, Dahinden CA, Helbling A (2004) Effect of tree pollen specific, subcutaneous immunotherapy on the oral allergy syndrome to apple and hazelnut. Allergy 59:1272–1276PubMedCrossRef Bucher X, Pichler WJ, Dahinden CA, Helbling A (2004) Effect of tree pollen specific, subcutaneous immunotherapy on the oral allergy syndrome to apple and hazelnut. Allergy 59:1272–1276PubMedCrossRef
26.
go back to reference Kulis M, Vickery BP, Burks AW (2011) Pioneering immunotherapy for food allergy: clinical outcomes and modulation of the immune response. Immunol Res 49:216–226PubMedCrossRef Kulis M, Vickery BP, Burks AW (2011) Pioneering immunotherapy for food allergy: clinical outcomes and modulation of the immune response. Immunol Res 49:216–226PubMedCrossRef
27.
go back to reference Beyer K, Wahn U (2008) Oral immunotherapy for food allergy in children. Curr Opin Allergy Clin Immunol 8:553–556PubMedCrossRef Beyer K, Wahn U (2008) Oral immunotherapy for food allergy in children. Curr Opin Allergy Clin Immunol 8:553–556PubMedCrossRef
28.
go back to reference Skripak JM, Nash SD, Rowley H, Brereton NH, Oh S et al (2008) A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow's milk allergy. J Allergy Clin Immunol 122:1154–1160PubMedCentralPubMedCrossRef Skripak JM, Nash SD, Rowley H, Brereton NH, Oh S et al (2008) A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow's milk allergy. J Allergy Clin Immunol 122:1154–1160PubMedCentralPubMedCrossRef
29.
go back to reference Longo G, Barbi E, Berti I, Meneghetti R, Pittalis A (2008) Specific oral tolerance induction in children with very severe cow's milk-induced reactions. J Allergy Clin Immunol 121:343–347PubMedCrossRef Longo G, Barbi E, Berti I, Meneghetti R, Pittalis A (2008) Specific oral tolerance induction in children with very severe cow's milk-induced reactions. J Allergy Clin Immunol 121:343–347PubMedCrossRef
30.
go back to reference Pajno GB, Caminiti L, Ruggeri P, De Luca R, Vita D (2010) Oral immunotherapy for cow's milk allergy with a weekly up-dosing regimen: a randomized single-blind controlled study. Ann Allergy Asthma Immunol 105:376–381PubMedCrossRef Pajno GB, Caminiti L, Ruggeri P, De Luca R, Vita D (2010) Oral immunotherapy for cow's milk allergy with a weekly up-dosing regimen: a randomized single-blind controlled study. Ann Allergy Asthma Immunol 105:376–381PubMedCrossRef
31.
go back to reference Buchanan AD, Green TD, Jones SM, Scurlock AM, Christie L (2007) Egg oral immunotherapy in nonanaphylactic children with egg allergy. J Allergy Clin Immunol 119:199–205PubMedCrossRef Buchanan AD, Green TD, Jones SM, Scurlock AM, Christie L (2007) Egg oral immunotherapy in nonanaphylactic children with egg allergy. J Allergy Clin Immunol 119:199–205PubMedCrossRef
32.
go back to reference Vickery BP, Pons L, Kulis M, Steele P, Jones SM (2010) Individualized IgE-based dosing of egg oral immunotherapy and the development of tolerance. Ann Allergy Asthma Immunol 105:444–450PubMedCentralPubMedCrossRef Vickery BP, Pons L, Kulis M, Steele P, Jones SM (2010) Individualized IgE-based dosing of egg oral immunotherapy and the development of tolerance. Ann Allergy Asthma Immunol 105:444–450PubMedCentralPubMedCrossRef
33.
go back to reference Clark AT, Islam S, King Y, Deighton J, Anagnostou K (2009) Successful oral tolerance induction in severe peanut allergy. Allergy 64:1218–1220PubMedCrossRef Clark AT, Islam S, King Y, Deighton J, Anagnostou K (2009) Successful oral tolerance induction in severe peanut allergy. Allergy 64:1218–1220PubMedCrossRef
34.
go back to reference Jones SM, Pons L, Roberts JL, Scurlock AM, Perry TT et al (2009) Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol 124:292–300PubMedCentralPubMedCrossRef Jones SM, Pons L, Roberts JL, Scurlock AM, Perry TT et al (2009) Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol 124:292–300PubMedCentralPubMedCrossRef
35.
go back to reference Varshney P, Jones SM, Scurlock AM, Perry TT, Kemper A et al (2011) A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol 127:654–660PubMedCentralPubMedCrossRef Varshney P, Jones SM, Scurlock AM, Perry TT, Kemper A et al (2011) A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol 127:654–660PubMedCentralPubMedCrossRef
36.
37.
go back to reference Fernandez-Rivas M, Garrido Fernandez S, Nadal JA, Diaz de Durana MD, Garcia BE et al (2009) Randomized double-blind, placebo-controlled trial of sublingual immunotherapy with a Pru p 3 quantified peach extract. Allergy 64:876–883PubMedCrossRef Fernandez-Rivas M, Garrido Fernandez S, Nadal JA, Diaz de Durana MD, Garcia BE et al (2009) Randomized double-blind, placebo-controlled trial of sublingual immunotherapy with a Pru p 3 quantified peach extract. Allergy 64:876–883PubMedCrossRef
38.
go back to reference Enrique E, Pineda F, Malek T, Bartra J, Basagana M et al (2005) Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract. J Allergy Clin Immunol 116:1073–1079PubMedCrossRef Enrique E, Pineda F, Malek T, Bartra J, Basagana M et al (2005) Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract. J Allergy Clin Immunol 116:1073–1079PubMedCrossRef
39.
go back to reference Kim EH, Bird JA, Kulis M, Laubach S, Pons L et al (2011) Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization. J Allergy Clin Immunol 127:640–646PubMedCentralPubMedCrossRef Kim EH, Bird JA, Kulis M, Laubach S, Pons L et al (2011) Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization. J Allergy Clin Immunol 127:640–646PubMedCentralPubMedCrossRef
40.
go back to reference Kinaciyan T, Jahn-Schmid B, Radakovics A, Zwolfer B, Schreiber C et al (2007) Successful sublingual immunotherapy with birch pollen has limited effects on concomitant food allergy to apple and the immune response to the Bet v 1 homolog Mal d 1. J Allergy Clin Immunol 119:937–943PubMedCrossRef Kinaciyan T, Jahn-Schmid B, Radakovics A, Zwolfer B, Schreiber C et al (2007) Successful sublingual immunotherapy with birch pollen has limited effects on concomitant food allergy to apple and the immune response to the Bet v 1 homolog Mal d 1. J Allergy Clin Immunol 119:937–943PubMedCrossRef
41.
go back to reference Senti G, von Moos S, Kundig TM (2011) Epicutaneous allergen administration: is this the future of allergen-specific immunotherapy? Allergy 66:798–809PubMedCrossRef Senti G, von Moos S, Kundig TM (2011) Epicutaneous allergen administration: is this the future of allergen-specific immunotherapy? Allergy 66:798–809PubMedCrossRef
43.
go back to reference Dupont C, Kalach N, Soulaines P, Legoue-Morillon S, Piloquet H et al (2010) Cow's milk epicutaneous immunotherapy in children: a pilot trial of safety, acceptability, and impact on allergic reactivity. J Allergy Clin Immunol 125:1165–1167PubMedCrossRef Dupont C, Kalach N, Soulaines P, Legoue-Morillon S, Piloquet H et al (2010) Cow's milk epicutaneous immunotherapy in children: a pilot trial of safety, acceptability, and impact on allergic reactivity. J Allergy Clin Immunol 125:1165–1167PubMedCrossRef
44.
go back to reference Ferreira F, Briza P, Infuhr D, Schmidt G, Wallner M et al (2006) Modified recombinant allergens for safer immunotherapy. Inflamm Allergy Drug Targets 5:5–14PubMedCrossRef Ferreira F, Briza P, Infuhr D, Schmidt G, Wallner M et al (2006) Modified recombinant allergens for safer immunotherapy. Inflamm Allergy Drug Targets 5:5–14PubMedCrossRef
45.
go back to reference Nowak-Wegrzyn A, Bloom KA, Sicherer SH, Shreffler WG, Noone S et al (2008) Tolerance to extensively heated milk in children with cow's milk allergy. J Allergy Clin Immunol 122:342–347PubMedCrossRef Nowak-Wegrzyn A, Bloom KA, Sicherer SH, Shreffler WG, Noone S et al (2008) Tolerance to extensively heated milk in children with cow's milk allergy. J Allergy Clin Immunol 122:342–347PubMedCrossRef
46.
go back to reference Lemon-Mule H, Sampson HA, Sicherer SH, Shreffler WG, Noone S et al (2008) Immunologic changes in children with egg allergy ingesting extensively heated egg. J Allergy Clin Immunol 122:977–983PubMedCrossRef Lemon-Mule H, Sampson HA, Sicherer SH, Shreffler WG, Noone S et al (2008) Immunologic changes in children with egg allergy ingesting extensively heated egg. J Allergy Clin Immunol 122:977–983PubMedCrossRef
47.
go back to reference Kim JS, Nowak-Wegrzyn A, Sicherer SH, Noone S, Moshier EL et al (2011) Dietary baked milk accelerates the resolution of cow's milk allergy in children. J Allergy Clin Immunol 128:125–131PubMedCentralPubMedCrossRef Kim JS, Nowak-Wegrzyn A, Sicherer SH, Noone S, Moshier EL et al (2011) Dietary baked milk accelerates the resolution of cow's milk allergy in children. J Allergy Clin Immunol 128:125–131PubMedCentralPubMedCrossRef
49.
go back to reference Chuang YH, Yang YH, Wu SJ, Chiang BL (2009) Gene therapy for allergic diseases. Curr Gene Ther 9:185–191PubMedCrossRef Chuang YH, Yang YH, Wu SJ, Chiang BL (2009) Gene therapy for allergic diseases. Curr Gene Ther 9:185–191PubMedCrossRef
50.
go back to reference Chua KY, Huangfu T, Liew LN (2006) DNA vaccines and allergic diseases. Clin Exp Pharmacol Physiol 33:546–550PubMedCrossRef Chua KY, Huangfu T, Liew LN (2006) DNA vaccines and allergic diseases. Clin Exp Pharmacol Physiol 33:546–550PubMedCrossRef
51.
go back to reference Li XM, Srivastava K, Grishin A, Huang CK, Schofield B et al (2003) Persistent protective effect of heat-killed Escherichia coli producing "engineered," recombinant peanut proteins in a murine model of peanut allergy. J Allergy Clin Immunol 112:159–167PubMedCrossRef Li XM, Srivastava K, Grishin A, Huang CK, Schofield B et al (2003) Persistent protective effect of heat-killed Escherichia coli producing "engineered," recombinant peanut proteins in a murine model of peanut allergy. J Allergy Clin Immunol 112:159–167PubMedCrossRef
52.
go back to reference DeLong JH, Simpson KH, Wambre E, James EA, Robinson D et al (2011) Ara h 1-reactive T cells in individuals with peanut allergy. J Allergy Clin Immunol 127:1211–1218PubMedCentralPubMedCrossRef DeLong JH, Simpson KH, Wambre E, James EA, Robinson D et al (2011) Ara h 1-reactive T cells in individuals with peanut allergy. J Allergy Clin Immunol 127:1211–1218PubMedCentralPubMedCrossRef
53.
go back to reference Li X, Huang CK, Schofield BH, Burks AW, Bannon GA et al (1999) Strain-dependent induction of allergic sensitization caused by peanut allergen DNA immunization in mice. J Immunol 162:3045–3052PubMed Li X, Huang CK, Schofield BH, Burks AW, Bannon GA et al (1999) Strain-dependent induction of allergic sensitization caused by peanut allergen DNA immunization in mice. J Immunol 162:3045–3052PubMed
54.
go back to reference Li XM, Zhang TF, Huang CK, Srivastava K, Teper AA et al (2001) Food Allergy Herbal Formula-1 (FAHF-1) blocks peanut-induced anaphylaxis in a murine model. J Allergy Clin Immunol 108:639–646PubMedCrossRef Li XM, Zhang TF, Huang CK, Srivastava K, Teper AA et al (2001) Food Allergy Herbal Formula-1 (FAHF-1) blocks peanut-induced anaphylaxis in a murine model. J Allergy Clin Immunol 108:639–646PubMedCrossRef
55.
go back to reference Srivastava KD, Kattan JD, Zou ZM, Li JH, Zhang L et al (2005) The Chinese herbal medicine formula FAHF-2 completely blocks anaphylactic reactions in a murine model of peanut allergy. J Allergy Clin Immunol 115:171–178PubMedCrossRef Srivastava KD, Kattan JD, Zou ZM, Li JH, Zhang L et al (2005) The Chinese herbal medicine formula FAHF-2 completely blocks anaphylactic reactions in a murine model of peanut allergy. J Allergy Clin Immunol 115:171–178PubMedCrossRef
56.
go back to reference Wang J, Patil SP, Yang N, Ko J, Lee J et al (2010) Safety, tolerability, and immunologic effects of a food allergy herbal formula in food allergic individuals: a randomized, double-blinded, placebo-controlled, dose escalation, phase 1 study. Ann Allergy Asthma Immunol 105:75–84PubMedCentralPubMedCrossRef Wang J, Patil SP, Yang N, Ko J, Lee J et al (2010) Safety, tolerability, and immunologic effects of a food allergy herbal formula in food allergic individuals: a randomized, double-blinded, placebo-controlled, dose escalation, phase 1 study. Ann Allergy Asthma Immunol 105:75–84PubMedCentralPubMedCrossRef
Metadata
Title
Novel Approaches to Food Allergy
Authors
Yao-Hsu Yang
Bor-Luen Chiang
Publication date
01-06-2014
Publisher
Springer US
Published in
Clinical Reviews in Allergy & Immunology / Issue 3/2014
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-013-8354-2

Other articles of this Issue 3/2014

Clinical Reviews in Allergy & Immunology 3/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine